Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbal Regulatory Category Creation At FDA Suggested By Sen. Durbin

This article was originally published in The Tan Sheet

Executive Summary

Sen. Dick Durbin (D-Ill.) is exploring the concept of a new regulatory scheme for dietary supplements that would create a separate regulatory category for herbal products

You may also be interested in...



DSHEA Legislative Reform Effort Likely In 108th Congress Behind Sen. Durbin

Legislation to amend the Dietary Supplement Health & Education Act is a long-term goal of Sen. Richard Durbin (D-Ill.), according to his staff

DSHEA Legislative Reform Effort Likely In 108th Congress Behind Sen. Durbin

Legislation to amend the Dietary Supplement Health & Education Act is a long-term goal of Sen. Richard Durbin (D-Ill.), according to his staff

DSHEA Legislative Reform Effort Likely In 108th Congress Behind Sen. Durbin

Legislation to amend the Dietary Supplement Health & Education Act is a long-term goal of Sen. Richard Durbin (D-Ill.), according to his staff

Related Content

Topics

UsernamePublicRestriction

Register

PS094359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel